Quantbot Technologies LP Global Blood Therapeutics, Inc. Transaction History

Quantbot Technologies LP

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 07, 2022	BUY	$32.4 - $68.18 $113,076 - $237,948	3,490 Added 51.25%	10,300 $701,000
Q2 2022 Aug 09, 2022	BUY	$22.3 - $37.39 $112,927 - $189,342	5,064 Added 290.03%	6,810 $217,000
Q1 2022 May 16, 2022	SELL	$25.68 - $35.59 $11,658 - $16,157	-454 Reduced 20.64%	1,746 $60,000
Q4 2021 Feb 11, 2022	BUY	$24.9 - $40.26 $54,780 - $88,572	2,200 New	2,200 $64,000
Q2 2020 Aug 13, 2020	SELL	$48.73 - $81.82 $17,445 - $29,291	-358 Closed	0 $0
Q1 2020 May 13, 2020	BUY	$41.72 - $87.2 $14,935 - $31,217	358 New	358 $18,000
Q3 2019 Nov 12, 2019	SELL	$45.35 - $57.91 $40,815 - $52,119	-900 Closed	0 $0
Q2 2019 Aug 13, 2019	BUY	$52.6 - $63.29 $47,340 - $56,961	900 New	900 $47,000
Q4 2018 Feb 13, 2019	SELL	$31.54 - $46.67 $59,610 - $88,206	-1,890 Closed	0 $0
Q3 2018 Nov 13, 2018	BUY	$38.0 - $51.1 $798 - $1,073	21 Added 1.12%	1,890 $71,000
Q2 2018 Aug 13, 2018	BUY	$38.7 - $50.15 $51,741 - $67,050	1,337 Added 251.32%	1,869 $84,000
Q1 2018 May 11, 2018	SELL	$39.6 - $65.9 $73,735 - $122,705	-1,862 Reduced 77.78%	532 $25,000
Q4 2017 Feb 12, 2018	BUY	$29.7 - $45.7 $53,103 - $81,711	1,788 Added 295.05%	2,394 $94,000
Q3 2017 Nov 07, 2017	BUY	$25.1 - $31.05 $15,210 - $18,816	606	606 $18,000

288K

Ticker GBT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,476,200
Market Cap $4.62B
Description
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses...

Get notified when there are updates to the investment portfolio of Quantbot Technologies LP, based on Form 13F filings with the SEC.

Stay updated on Quantbot Technologies LP with notifications on news.